Department of Clinical Research, University of Connecticut, Farmington, Belgium
Perspective
p53 Mutation-Targeting Medications Approved by the FDA and in Clinical Trials
Author(s): Zhou Huan*
About half of all cancers in humans have mutations in the tumor suppressor p53 (p53), most of which are missense mutations. Not only do p53
mutations impair its ability to suppress drugs, but they also give the missense mutant p53 (mutp53) oncogenic properties that are distinct from
those of the wild-type p53. Restoring or stabilizing wtp53 conformation from mutp53, rescuing p53 nonsense mutations, depleting mutp53 proteins
and inducing p53 synthetic lethality or targeting vulnerabilities imposed by p53 deficiencies (activated retrotransposons) or mutations (enhanced
YAP/TAZ) are some of the approaches that have been taken to develop novel cancer therapies because p53 mutations are specific to cancer. The
mechanisms of action and activities of FDA-approved and clinically available drugs that target p53 mutations to stop the progression of cancer are
summarized here C.. Read More»
DOI:
10.37421/2472-1247.2023.9.254
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 